WO1997018774A1 - Method of treating involuntary muscle dysfunction with relaxin hormone - Google Patents
Method of treating involuntary muscle dysfunction with relaxin hormone Download PDFInfo
- Publication number
- WO1997018774A1 WO1997018774A1 PCT/US1996/018073 US9618073W WO9718774A1 WO 1997018774 A1 WO1997018774 A1 WO 1997018774A1 US 9618073 W US9618073 W US 9618073W WO 9718774 A1 WO9718774 A1 WO 9718774A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- relaxin
- hormone
- therapeutically effective
- effective amount
- administering
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2221—Relaxins
Definitions
- the present invention relates to the treatment of involuntary muscle dysfunctions.
- the present invention relates to the treatment of involuntary muscle dysfunction with relaxin hormone.
- Involuntary muscle dysfunction plagues a large portion of the chronic pain and chronic fatigue patient population.
- Two prominent conditions involving involuntary muscle dysfunction include fibromyalgia and myofascial pain syndrome, amongst others.
- Fibromyalgia is the second or third most common disorder seen in community practice. The economic effects of fibromyalgia are substantial.
- Fibromyalgia also appears to be concentrated amongst the female patient population. It is estimated that about 80 to 90 % of fibromyalgia patients are women. In addition, most patients are reported to fall in the 40 to 50 year age range. However, some studies have identified an archetypical patient as being a young women between the ages of 20 and 40. See Masi, A. , Review of The Epidemiology and Criteria of Fibromyalgia and Myofascial Pain Syndromes: Concepts of Illness in Populations as Applied to Dysfunctional Syndromes, Journal of Musculoskeletal Pain, 1993, Vol. 1, pp. 113-116. See also Yunnus, supra, page 6.
- the present invention is based on the recognition that the involuntary muscle dysfunctions associated with fibromyalgia, myofascial pain syndrome, dystonia, chronic fatigue syndrome, and other conditions is the result of a deficiency of relaxin hormone or a suppression of relaxin' s effect in the bloodstream.
- This lack of relaxin in the blood stream may be congenital or the result of another mechanism which suppresses the normal production or action of relaxin.
- a method of the present invention of treating involuntary muscle dysfunction comprises administering to a patient exhibiting symptoms associated with these conditions a therapeutically effective amount of relaxin hormone.
- the relaxin hormone will alleviate these conditions since relaxin acts to effect collagen formation and remodelling, thereby causing tissue changes of the type associated with parturition, i.e., smooth muscle relaxation, elongation of tendons and ligaments, etc.
- fibromyalgia patients report that their pain -related symptoms subside during pregnancy and return after pregnancy.
- This relationship is significant since the vast majority of fibromyalgia patients are women.
- the disappearance of fibromyalgia symptoms in these patients when pregnant is explained by the relatively high elevation of relaxin during pregnancy.
- This recognition of relaxin as the primary causal agent in involuntary muscle dysfunction is confirmed by clinical observations by the inventor of patients with premenstrual pain syndrome (PMS). Women that have fibromyalgia or myofascial pain syndrome frequently have dysmenorrhea, reporting that their symptoms are aggravated just before and during the menstrual period.
- PMS premenstrual pain syndrome
- the level of relaxin typically rises in women about 7-10 days after the midcycle surge of the luteinizing hormone and when conception does not occur, the level falls precipitously about one week before the menstrual period begins.
- the inventor has observed that female patients with PMS, fibromyaglia or myfascial pain syndrome with dysmenorrhea, all report an increase or beginning of their painful symptoms and muscle tension and discomfort one week before and during the menstrual period.
- the precipitously falling level of the circulating relaxin corresponds to the beginning or increase in the level of patients' pain and discomfort one week before and during the menstrual period.
- Administering relaxin to patients with fibromyalgia, myofascial pain syndrome and related involuntary muscle dysfunctions is expected to significantly alleviate the core symptoms of these conditions, e.g., generalized pain and tenderness, as well as alleviate specific secondary symptoms such as dysmenorrhea.
- relaxin remodels the reproductive tract which includes ripening of the cervix, thickening of the endometrium of the uterus, increasing vascularization ofthe uterus, and affecting collagen synthesis to cause ligaments and connective tissue to elongate and relax. It has also been observed that Raynaud's lesions completely disappear during early pregnancy. This observation has been loosely associated with the elevation of circulating relaxin. There also have been reports on relaxin's effect on cardiac output and specifically relaxin's ability to increase the rate of contraction ofthe right atrium and force of contraction of the left atrium of the heart. See Cronin, U.S. Patent 5,166,191.
- the relaxin hormone will alleviate these conditions since relaxin acts to effect collagen formation and collagen remodelling.
- Relaxin will alleviate the generalized pain and tenderness by elongating muscles and accentuating joint laxity by remodelling connective tissue (e.g ligaments, tendons, bone, etc.) via collagen changes.
- connective tissue e.g ligaments, tendons, bone, etc.
- This expected effect is based on many studies that have observed that pregnant women have elongated pelvic area muscles, and increased joint laxity resulting from the remodelling effect induced by relaxin. This recognition is based on clinical observations by the inventor of the symptoms reported by female patients with fibromyalgia or myofascial pain syndrome when these patients are pregnant or in menopause.
- fibromyalgia patients and myofascial pain syndrome patients do not report or exhibit the same symptoms (generalized pain, fatigue, inflexibility) when they are pregnant that they report when they are not pregnant. In short, many or all of the symptoms associated with these conditions disappear when the patients are pregnant. These female fibromyalgia patients also report an aggravation of their symptoms after menopause. These relationships are significant since the vast majority of fibromyalgia patients are women.
- fibromyalgia patients have generalized pain and other symptoms starting from their teenage years. The inventor believes that these patients suffer due to a congenital maldevelopment of the organs (e.g ovary) or other sites that produce relaxin, which in turn inhibits or suppresses relaxin production.
- the beginning of fibromyalgia is likely marked by menarche (beginning of menstruation).
- menarche beginning of menstruation
- the pain is generalized overall and increases in intensity as the patient gets bigger and acquires more musculature.
- these patients mature are in constant pain when in a non-pregnant state yet have almost no generalized pain symptoms when pregnant. However, the classic symptoms return when the pregnancy is over.
- Relaxin can be viewed as a lubricant on the body allowing collagen to remodel itself, thereby permitting the musculature and connective tissue to continue to function like a young person's musculature. Alternatively, normal production of relaxin may decrease as we age, thereby necessitating relaxin supplementation to maintain muscle relaxation and connective tissue flexibility.
- relaxin While the administration of relaxin to fibromyalgia and myofascial pain patients is expected to alleviate the core symptoms of generalized pain, hyperalgesia (multiple tender points), and inflexibility, the inventor also believes that relaxin will have a substantial effect on related symptoms involving smooth muscle dysfunction.
- Fibromyaglia patients also have other symptoms related to smooth muscle control including gastrointestinal tract difficulties, urinary tract difficulties, and pelvic dysfunctions. Gastrointestinal difficulties include bowel and intestinal dysfunction while urinary difficulties include bladder and urethral dysfunctions.
- Urinary difficulty results from tight sphincter muscle tone on the bladder while vaginismus is extra tight contraction of the vagina when these muscles go into spasm. This can result in difficulty during sexual intercourse, passing stool, and passing urine.
- Pelvic floor myalgia or pelvic floor dysfunction including dysfunctions in micturition (urination), evacuation of the bowel, and sexual functions are believed to be treatable with relaxin because of relaxin's effect on smooth muscle. In particular, the inventor believes that relaxin will reduce the amount of tone exhibited by the smooth muscles regulating these activities.
- premenstrual syndrome is a subclinical form of myofascial pain syndrome with obvious pelvic floor congestion and dysfunction, irritable bowel syndrome and hyperactive uterus. All of these symptoms are related to high smooth muscle tone and activities and appear a week before and during the menstrual period. Therefore, these reactive events within the pelvic floor are related to the precipitous fall of the relaxin level prior to the menstrual period. Based on this clinical observation, the inventor believes that these symptoms should be alleviated with relaxin which would relax the smooth muscles affecting those pelvic functions.
- dysmenorrheic women In addition to muscle pain and dysfunction in the reproductive tract region, dysmenorrheic women also have heightened sensitivity to pain in unrelated regions of the body (e.g. , deltoid muscle and quadriceps muscle). See Berkley et al., Muscle Pain Thresholds In Dysmenorrheic Versus Normal Women: Variations as a Function of Segmental Site and Monthly Cycle, Abstract 3rd World Congress on Myofascial Pain & Fibromyalgia, San Antonio, Texas, 1995.
- Chronic fatigue syndrome is a different manifestation of fibromyalgia.
- fibromyalgia the primary manifestation of a lack of relaxin is pain with muscle fatigue as a secondary manifestation and that in chronic fatigue syndrome, muscle fatigue is the primary manifestation of a lack of relaxin with pain being secondary.
- Chronic fatigue syndrome results from the muscles fatiguing prematurely from operating inefficiently. Extra efforts are required to initiate contraction of the stiff striated muscles causing an excessive amount of fatigue. The inventor believes that this inefficient muscle operation and associated muscle fatigue results from a congenital lack of relaxin.
- Other trauma such as removal of the ovary or glandular problems in the male might inhibit the production of relaxin, and thereafter acquire a relaxin deficit and present patients with fibromyalgia like symptoms.
- relaxin can be applied topically to the epidermis to cause collagen remodelling, thereby increasing the elasticity and function of the skin.
- relaxin can be applied topically to the epidermis to cause collagen remodelling, thereby increasing the elasticity and function of the skin.
- Another example would be the infusion of a therapeutic level of relaxin to abort the pain associated with vasospastic events of the body and vasomotor events within the cranium.
- Relaxin is known to be structurally similar to insulin. See Burnier et al., U.S. Patent No. 4,835,251. Accordingly, relaxin is expected to be introducible into the body in a manner substantially similar to insulin. Relaxin and its analogs can be formulated using known methods to prepare pharmaceutically useful compositions by combining relaxin with a pharmaceutically acceptable carrier. Suitable carriers and their formulation are known in the art. See also U.S. Patent No. 4,835,251.
- relaxin can be administered by a carrier and formulation similar to an insulin zinc suspension sold by Eli Lilly of Indianapolis Indiana under the trademark LENTE* ILETTN ® .
- This product is an amorphous and crystalline suspension of insulin with zinc providing an intermediate acting insulin with a slower onset and a longer duration of activity (slightly more than 24 hours) than regular insulin.
- the duration of action of course, being dependent on dose, site of injection, blood supply, temperature and physical activity.
- a formulation like HUMULEN ® for insulin of recombinant DNA origin would be well suited to act as a carrier.
- relaxin can be applied vaginally or rectally by using a suppository as a drug delivery vehicle.
- relaxin can be incorporated into suppository system like a rectal suppository sold under the trade name PROCHLORPERAZINE ® suppositories or like a vaginal suppository sold under the trademark MONISTAT 7 ® (used for administering miconazole nitrate).
- a baseline dose for human patients is preferably determined for a given administration route by administering to a group of patients a control amount of relaxin equal to the normal level of relaxin in the human body during nonpregnant states (for women) and then further administering to other groups of patients increasing amounts of relaxin at two times, four times, and eight times, respectively, the control level of circulating relaxin to determine the dosage at which 90 % of the patients report good pain relief.
- the level at which 90% of the patients report alleviation of pain and other symptoms of involuntary muscle dysfunction will be the baseline dose which can be modified as necessary for specific patient conditions.
- relaxin may be desirable or necessary to couple administration of relaxin with any one of estrogen, progesterone, and testosterone, or a combination thereof such as estrogen and progesterone, to achieve the desired synthesis and elevation of relaxin in the blood stream.
- topical administration of relaxin relates to joint pain and tightness. Specifically, some joints such as the knee, elbow, wrist, ankles and even the lower back experience wear and tear from repeated use and in some cases overuse resulting in tendinitis (e.g. tennis elbow). Typically, in these situations, treatment is directed to reducing inflammation at the joint. However, the inflammation is secondary to the primary problem: tightness of the ligaments and muscles in the joint.
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96941987A EP1014885A4 (en) | 1995-11-17 | 1996-11-14 | Method of treating involuntary muscle dysfunction with relaxin hormone |
AU11186/97A AU1118697A (en) | 1995-11-17 | 1996-11-14 | Method of treating involuntary muscle dysfunction with relaxin hormone |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/560,492 US5612051A (en) | 1995-11-17 | 1995-11-17 | Method of treating involuntary muscle dysfunction with relaxin hormone |
US08/560,492 | 1995-11-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997018774A1 true WO1997018774A1 (en) | 1997-05-29 |
Family
ID=24238037
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/018073 WO1997018774A1 (en) | 1995-11-17 | 1996-11-14 | Method of treating involuntary muscle dysfunction with relaxin hormone |
Country Status (5)
Country | Link |
---|---|
US (4) | US5612051A (en) |
EP (1) | EP1014885A4 (en) |
AU (1) | AU1118697A (en) |
CA (1) | CA2238018A1 (en) |
WO (1) | WO1997018774A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7878978B2 (en) | 2004-03-18 | 2011-02-01 | University Of Pittsburgh- Of The Commonwealth System Of Higher Education | Use of relaxin to increase arterial compliance |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6861053B1 (en) * | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
US6562629B1 (en) | 1999-08-11 | 2003-05-13 | Cedars-Sinai Medical Center | Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum |
US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
US6056972A (en) * | 1997-02-26 | 2000-05-02 | Dimera, Llc | Method for reducing coronary artery reactivity |
US5895787A (en) * | 1997-10-08 | 1999-04-20 | Designed Nutritional Products, Inc. | Treatment of fibromyalgia and related disorders |
US6627746B1 (en) | 1998-04-17 | 2003-09-30 | Exelixis, Inc. | Nucleic acids and proteins of C. elegans insulin-like genes and uses thereof |
US6251863B1 (en) | 1998-09-08 | 2001-06-26 | Samuel K. Yue | Method of preventing and treating symptoms of aging and neurodegenerative dysfunctions with relaxin |
EP1152761B1 (en) * | 1999-02-18 | 2009-06-24 | Novasearch AG | Use of 5-ht3 receptor antagonists for treating musculoeskeletal diseases |
US6610324B2 (en) * | 1999-04-07 | 2003-08-26 | The Mclean Hospital Corporation | Flupirtine in the treatment of fibromyalgia and related conditions |
US6610674B1 (en) * | 1999-09-28 | 2003-08-26 | University Of Pennsylvania | Method of treating inflammatory conditions with progesterone analogs |
US20050032683A1 (en) | 2000-10-04 | 2005-02-10 | Amento Edward P. | Methods of modulating apoptosis by administration of relaxin agonists or antagonists |
US6436448B1 (en) * | 2001-06-25 | 2002-08-20 | Sky Biohealth Solutions, Inc. | Method for the treatment of lymphedema using guaifenesin |
US6623742B2 (en) | 2001-09-17 | 2003-09-23 | Allergan, Inc. | Methods for treating fibromyalgia |
US7255866B2 (en) | 2001-09-17 | 2007-08-14 | Allergan, Inc. | Botulinum toxin therapy for fibromyalgia |
US20030124174A1 (en) * | 2001-10-25 | 2003-07-03 | Endo Pharmaceuticals, Inc | Method for treating non-neuropathic pain |
US20050020970A1 (en) * | 2002-09-06 | 2005-01-27 | Medtronic, Inc. | Method, system and device for treating disorders of the pelvic floor by delivering drugs to the pudendal nerves |
US7328068B2 (en) * | 2003-03-31 | 2008-02-05 | Medtronic, Inc. | Method, system and device for treating disorders of the pelvic floor by means of electrical stimulation of the pudendal and associated nerves, and the optional delivery of drugs in association therewith |
US7369894B2 (en) | 2002-09-06 | 2008-05-06 | Medtronic, Inc. | Method, system and device for treating disorders of the pelvic floor by electrical stimulation of the sacral and/or pudendal nerves |
US7328069B2 (en) * | 2002-09-06 | 2008-02-05 | Medtronic, Inc. | Method, system and device for treating disorders of the pelvic floor by electrical stimulation of and the delivery of drugs to the left and right pudendal nerves |
US7276057B2 (en) * | 2002-09-06 | 2007-10-02 | Medtronic, Inc. | Method, system and device for treating disorders of the pelvic floor by drug delivery to the pudendal and sacral nerves |
US7427280B2 (en) * | 2002-09-06 | 2008-09-23 | Medtronic, Inc. | Method, system and device for treating disorders of the pelvic floor by delivering drugs to various nerves or tissues |
US20050186526A1 (en) * | 2002-11-01 | 2005-08-25 | Bas Medical, Inc. | Methods and systems for enabling and stabilizing tooth movement |
US6984128B2 (en) * | 2002-11-01 | 2006-01-10 | Bas Medical, Inc. | Methods for enabling and stabilizing tooth movement |
US7572780B2 (en) * | 2003-01-21 | 2009-08-11 | Dimera, Incorporated | Method and kit for reducing the symptoms of peripheral vascular disease |
US20060178354A1 (en) * | 2003-02-27 | 2006-08-10 | Lucas John M | Methods and compositions for the treatment of chronic pain using dhea and derivatives thereof |
US8467875B2 (en) | 2004-02-12 | 2013-06-18 | Medtronic, Inc. | Stimulation of dorsal genital nerves to treat urologic dysfunctions |
US20060052304A1 (en) * | 2004-09-02 | 2006-03-09 | Bas Medical, Inc. | Method for remodeling bone and related sutures |
ES2281222B1 (en) * | 2004-09-24 | 2008-06-01 | Grifols, S.A. | USE OF ALFA-1 ANTITRIPSIN FOR THE PREPARATION OF MEDICINES FOR THE TREATMENT OF FIBROMIALGIA. |
US7527614B2 (en) * | 2005-03-25 | 2009-05-05 | Kimberly-Clark Worldwide, Inc. | Protective tube for a medicated tampon |
US7993667B2 (en) * | 2005-03-25 | 2011-08-09 | Kimberly-Clark Worldwide, Inc. | Methods of manufacturing a medicated tampon assembly |
US7744556B2 (en) * | 2005-03-25 | 2010-06-29 | Kimberly-Clark Worldwide, Inc. | Delivery tube assembly for an applicator |
US7919453B2 (en) * | 2005-03-25 | 2011-04-05 | Kimberly-Clark Worldwide, Inc. | Dosage cap assembly for an applicator |
US9295289B2 (en) * | 2005-04-01 | 2016-03-29 | Leslie Jane James | Waist-fastening, hip-encompassing apparel with at least one concealed storage compartment |
US7708726B2 (en) * | 2005-04-28 | 2010-05-04 | Kimberly-Clark Worldwide, Inc. | Dosage form cap for an applicator |
US20070141118A1 (en) * | 2005-12-15 | 2007-06-21 | Damico Joyce A | Layered dosage form for a medicated tampon assembly |
US20070255333A1 (en) * | 2006-04-28 | 2007-11-01 | Medtronic, Inc. | Neuromodulation therapy for perineal or dorsal branch of pudendal nerve |
PT2288367E (en) * | 2008-05-16 | 2016-02-09 | Corthera Inc | H2 relaxin for use in the treatment of premature cervical dilation |
WO2011112791A1 (en) * | 2010-03-10 | 2011-09-15 | Corthera, Inc | Modulating aquaporins with relaxin |
EP3936133A1 (en) | 2011-11-23 | 2022-01-12 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
AU2014261111B2 (en) | 2013-05-02 | 2017-03-16 | Glaxosmithkline Intellectual Property Development Limited | Therapeutic peptides |
CA2924109A1 (en) | 2013-09-13 | 2015-03-19 | The California Institute For Biomedical Research | Modified therapeutic agents and compositions thereof |
KR102455171B1 (en) | 2013-12-18 | 2022-10-14 | 더 스크립스 리서치 인스티튜트 | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof |
KR20170005819A (en) | 2014-05-22 | 2017-01-16 | 쎄러퓨틱스엠디, 인코퍼레이티드 | Natural combination hormone replacement formulations and therapies |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
AU2017239645A1 (en) | 2016-04-01 | 2018-10-18 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5478807A (en) * | 1991-08-19 | 1995-12-26 | Genentech, Inc. | Use of relaxin in the treatment of bradycardia |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4267101A (en) * | 1980-02-01 | 1981-05-12 | Serono Laboratories Inc. | Process for obtaining human relaxin from fetal membranes |
US4656249A (en) * | 1982-06-10 | 1987-04-07 | Howard Florey Institute Of Experimental Physiology And Medicine | Peptides with relaxin activity |
US5320953A (en) * | 1982-08-12 | 1994-06-14 | Howard Florey Institute Of Experimental Physiology And Medicine | Process for synthesizing human H1-prorelaxin, H1-relaxin and fusion proteins thereof |
US5145962A (en) * | 1982-08-12 | 1992-09-08 | Howard Florey Institute Of Experimental Physiology And Medicine | Human pro relaxin polypeptides |
DE3236264A1 (en) * | 1982-09-30 | 1984-04-05 | Serono Pharmazeutische Präparate GmbH, 7800 Freiburg | METHOD FOR OBTAINING RELAXIN |
US5023321A (en) * | 1982-12-13 | 1991-06-11 | Howard Florey Institute Of Experimental Physiology & Medicine | Molecular cloning and characterization of a further gene sequence coding for human relaxin |
US5179195A (en) * | 1982-12-13 | 1993-01-12 | Howard Florey Institute Of Experimental Physiology And Medicine | Human relaxin polypeptides |
CH661662A5 (en) * | 1984-04-16 | 1987-08-14 | Georg L Prof Dr Floersheim | Product for the treatment of the skin and of the connective tissue |
US4835251A (en) * | 1986-06-23 | 1989-05-30 | Genetech, Inc. | Method of chain combination |
AU626840B2 (en) * | 1988-02-26 | 1992-08-13 | Genentech Inc. | Human relaxin formulation |
US5108897A (en) * | 1988-09-30 | 1992-04-28 | Cornell Research Foundation, Inc. | Relaxin testing for early detection of pregnancy in dogs |
DE69001248T2 (en) * | 1989-05-04 | 1993-10-14 | Genentech Inc | METHOD AND COMPOSITIONS FOR INSULATING HUMAN RELAXIN. |
US5089419A (en) * | 1989-08-07 | 1992-02-18 | International Canine Genetics | Detection of pregnancy by identification of the c peptide of relaxin in the urine of animals |
US5223408A (en) * | 1991-07-11 | 1993-06-29 | Genentech, Inc. | Method for making variant secreted proteins with altered properties |
US5166191A (en) * | 1991-08-19 | 1992-11-24 | Genentech, Inc. | Use of relaxin in cardiovascular therapy |
AU691189B2 (en) * | 1993-06-21 | 1998-05-14 | Genentech Inc. | Process for producing relaxin |
US5656592A (en) * | 1993-09-29 | 1997-08-12 | Seed; Brian | Use of relaxin as an analgesic and palliative for intractable pain |
IL107167A (en) * | 1993-10-03 | 2000-01-31 | Raziel Lurie | Compositions containing relaxin for treatment of alopecia and related conditions |
US5811388A (en) * | 1995-06-07 | 1998-09-22 | Cibus Pharmaceutical, Inc. | Delivery of drugs to the lower GI tract |
US5811395A (en) * | 1995-06-07 | 1998-09-22 | Medical University Of South Carolina | Relaxin analogs and derivatives methods and uses thereof |
US5753623A (en) * | 1995-06-07 | 1998-05-19 | Connetics Corporation | Method of treatment for depression |
-
1995
- 1995-11-17 US US08/560,492 patent/US5612051A/en not_active Expired - Fee Related
-
1996
- 1996-11-14 CA CA002238018A patent/CA2238018A1/en not_active Abandoned
- 1996-11-14 EP EP96941987A patent/EP1014885A4/en not_active Withdrawn
- 1996-11-14 AU AU11186/97A patent/AU1118697A/en not_active Abandoned
- 1996-11-14 WO PCT/US1996/018073 patent/WO1997018774A1/en not_active Application Discontinuation
-
1997
- 1997-02-11 US US08/802,340 patent/US5707642A/en not_active Expired - Fee Related
-
1998
- 1998-01-09 US US09/005,383 patent/US5863552A/en not_active Expired - Fee Related
- 1998-11-19 US US09/196,292 patent/US6048544A/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5478807A (en) * | 1991-08-19 | 1995-12-26 | Genentech, Inc. | Use of relaxin in the treatment of bradycardia |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7878978B2 (en) | 2004-03-18 | 2011-02-01 | University Of Pittsburgh- Of The Commonwealth System Of Higher Education | Use of relaxin to increase arterial compliance |
US8602998B2 (en) | 2004-03-18 | 2013-12-10 | University of Pittsburgh—of the Commonwealth System of Higher Education | Use of relaxin to increase arterial compliance |
Also Published As
Publication number | Publication date |
---|---|
US5863552A (en) | 1999-01-26 |
EP1014885A4 (en) | 2002-01-09 |
EP1014885A1 (en) | 2000-07-05 |
US5707642A (en) | 1998-01-13 |
AU1118697A (en) | 1997-06-11 |
US6048544A (en) | 2000-04-11 |
US5612051A (en) | 1997-03-18 |
CA2238018A1 (en) | 1997-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5612051A (en) | Method of treating involuntary muscle dysfunction with relaxin hormone | |
US6251863B1 (en) | Method of preventing and treating symptoms of aging and neurodegenerative dysfunctions with relaxin | |
ichael Ludwig et al. | Use of recombinant human chorionic gonadotropin in ovulation induction | |
Hisaw | The placental gonadotrophin and luteal function in monkeys (Macaca mulatta) | |
KR101730517B1 (en) | Monolithic intravaginal rings comprising progesterone and methods of making and use thereof | |
US5700781A (en) | Method for treating Kaposi's sarcoma and HIV infections | |
US5880093A (en) | Use of parathormone, its biologically active fragments and correlated peptides, for the preparation of pharmaceutical compositions useful for the treatment of pregnancy | |
Shorr | The menopause | |
Bagne111 et al. | Sources and biological actions of relaxin in pigs | |
JPS6176421A (en) | Ovulation induction and in vitro fertilization | |
US5700775A (en) | Method and treatment composition for decreasing patient time in catabolic state after traumatic injury | |
Franz III | Basic review: endocrinology of the normal menstrual cycle | |
Van Wagenen | UTERINE BLEEDING OF MONKEYS IN RELATION TO NEURAL AND VASCULAR PROCESSES: I. Spinal Transection and Menstruation | |
PL211113B1 (en) | Use of fsh for treating infertility | |
Buttle | The luteotrophic complex in hysterectomized and pregnant goats. | |
EP0474787B1 (en) | A process for treating infertility and an agent for use in the process | |
Stys | Endocrine regulation of cervical functions during pregnancy and labor | |
JPH07505860A (en) | Use of interleukin-8 | |
Leathem | Experimental induction of estrus in the dog | |
US5538948A (en) | Method for treating infertility comprising administering GnRH analog, gonadotrophins, and growth hormone | |
Shaw et al. | Endocrine changes following pituitary desensitization with LHRH agonist and administration of purified FSH to induce follicular maturation | |
Larson et al. | The bovine estrous cycle and synchronization of estrus | |
CA2515297A1 (en) | Use of human chorionic gonadotropin in the treatment of symptoms caused by endometriosis | |
Arora et al. | Emerging drug delivery in the treatment of hyperpituitarism and hypopituitarism | |
Ziporyn | LHRH: clinical applications growing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2238018 Country of ref document: CA Ref country code: CA Ref document number: 2238018 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996941987 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97519773 Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1996941987 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996941987 Country of ref document: EP |